Global Flow Cytometry Market Size, Share, Growth Analysis, By Products(Instruments (Cell Analyzers, Cell Sorters)), By Technology(Cell-based, Bead-based), By Application(Research (Pharmaceutical (Drug Discovery, Stem Cell), By End-Use(Commercial Organizations, Hospitals) - Industry Forecast 2022-2028

The Global Flow Cytometry Market is segmented based on Product, Technology, Application, End-use, and Region. Based on Product it is categorized into: Instruments (Cell Analyzers, Cell Sorters), Reagents & Consumables, Software, Accessories, and Services. Based on Technology it is categorized into: Cell-based, Bead-based. Based on Application it is categorized into: Research (Pharmaceutical (Drug Discovery, Stem Cell, and In Vitro Toxicity), Apoptosis, Cell Sorting, Cell Cycle Analysis, Immunology, Cell Viability), Industrial, Clinical (Cancer, Organ Transplantation, Immunodeficiency, and Hematology). Based on End-use it is categorized into: Commercial Organizations, Hospitals, Academic Institutes, and Clinical Testing Labs. Based on region it is categorized into: North America, Europe, Asia-Pacific, South America, and MEA.

Analysis by Product

The instruments segment dominated the flow cytometry market in 2021 and is expected to maintain its dominance throughout the forecast period. This high share could be attributed to technological advancements and the introduction of novel cytometers by key players. The high cost of these instruments also contributes to the segment's high revenue generation. Because of their increased adoption in diagnostics and research, the reagents and consumables segment held a significant revenue share in the flow cytometry market in 2021. Over the forecast period, the segment is expected to grow at a rapid pace.

Analysis by Application

The research segment dominated the Flow Cytometry market in 2021 and is expected to maintain its dominance throughout the forecast period. This high share can be attributed to increased R&D activities in cancer and infectious diseases, such as COVID-19. Moreover, rising R&D investments in the pharmaceutical and biotechnology industries are expected to create a favorable environment for market growth. Clinical diagnosis is expected to be the fastest-growing segment, owing to the rising demand for low-cost disease diagnosis and the associated benefits of flow cytometry in disease detection, such as faster and more accurate results. Furthermore, prominent players' ongoing organic growth strategies, as well as the introduction of novel flow cytometry solutions for clinical applications, are expected to significantly support the Flow Cytometry market growth.

Analysis by End-use

The commercial organization segment dominated the flow cytometry market. This dominance can be attributed to increased R&D efforts by commercial organizations such as pharmaceutical and biotechnology firms. Moreover, expanding food industries in developing countries such as China and India are expected to drive segment growth. Furthermore, increased commercial research activities to develop effective therapeutics for life-threatening diseases such as cancer are expected to drive high demand for flow cytometry solutions. on the other hand, the hospitals and clinical testing labs segment are expected to grow rapidly due to the rising demand for cost-effective diagnoses of target diseases such as cancer.

In 2021, North America dominated the flow cytometry market. Throughout the study period, the region is expected to dominate the market. This dominance can be attributed to the United States' high healthcare spending, well-established healthcare infrastructure, and widespread adoption of technologically advanced flow cytometry solutions. Furthermore, the established pharmaceutical industry, as well as extensive research activities by research universities and pharmaceutical companies, have created a significant demand for flow cytometry solutions for research purposes. During the forecast period, the Flow Cytometry market in the Asia Pacific is expected to grow at an exponential rate. This region's profitable growth is also a result of ongoing government support for the establishment of the pharmaceutical industry in developing markets.

Driver

• Flow cytometry aids in the analysis of cell surface and intracellular molecule expression. It is used to characterize and define various types of cells in a heterogeneous cell population, as well as to assess the purity of isolated subpopulations. The Flow Cytometry market is being driven by rising R&D initiatives by various key players for the development of multicolor assays and advanced reagents for analysis.
• The rising prevalence of chronic and infectious diseases, including the COVID-19 outbreak, has resulted in rapid growth in the flow cytometry market. Following the outbreak, numerous research institutes and pharmaceutical companies have engaged in extensive R&D activities to develop new vaccines and therapies. This has resulted in high demand for flow cytometry solutions for research purposes.
• The biotechnology industry is expected to grow substantially over the forecast period as a result of rising healthcare expenditures in developed countries and the improvement of healthcare facilities. The Flow Cytometry market is expected to be driven by an increase in government funding for clinical studies involving in vitro molecular diagnostics.

Restraint

• Flow cytometry instruments are expensive, and many developing economies cannot afford technologically advanced flow cytometers. These instruments cost between USD 75,000 and USD 100,000 for a four- to six-color and two-laser instrument, posing a significant financial burden on small and medium-sized hospitals and diagnostic laboratories in developing economies. Thermo Fisher Scientific's Attune with a two-laser and six-color instrument costs USD 99,000 in the United States. As a result, the high cost of equipment will likely limit demand for advanced flow cytometers.

The flow cytometry market is considered highly consolidated due to the presence of very few players in the market. These players are holding a huge share of the market and are likely to remain in a similar competitive environment for the next few years. Key Flow Cytometry market players in the market are Becton, Dickinson and Company, Danaher Corporation Sysmex Corporation, Bio-Rad Laboratories Inc, Luminex Corporation, etc.

Top Players Company Profiles

• Becton, Dickinson, and Company (US)
• Danaher Corporation (US)
• Thermo Fisher Scientific, Inc. (US)
• Luminex Corporation (US)
• Agilent Technologies, Inc. (US)
• Sony Group Corporation (Japan)
• Bio-Rad Laboratories, Inc. (US)
• Miltenyi Biotec GmbH (Germany)
• Enzo Biochem, Inc. (US)
• Sysmex Corporation (Japan)
• bioMérieux S.A. (France)
• Cytonome/ ST, LLC (US)
• Sartorius AG (Germany)
• Cytek Biosciences, Inc. (US)
• Union Biometrica, Inc. (US)

Recent Developments

• In June 2022, Becton, Dickinson, and Company announced the launch of new cell sorting technology at the International Society for Advancement of Cytometry (ISAC) CYTO 2022 conference. This new technology allows researchers to see and sort cells at speeds never before possible, potentially transforming research and cell-based therapeutic development across a variety of fields, including virology and oncology, as well as a variety of disease states.
• In August 2021, Becton, Dickinson, and Company introduced the BD FACSymphony A1 Cell Analyzer, a new benchtop cell analyzer. The fluorescence-activated cell analyzer is expected to provide sophisticated flow cytometry capabilities to laboratories of all sizes.
• In June 2021, The Invitrogen Attune CytPix Flow Cytometer from Thermo Fisher Scientific is an imaging-enhanced flow cytometer that combines acoustic focusing flow cytometry technology with a high-speed camera.

• Flow cytometry is considered as an excellent tool for characterizing, identifying, and isolating stem cells for research and potential clinical applications. Recent advances in flow cytometric hardware, reagents, and software have enabled stem cell biologists to more fully identify and isolate rare cells. With such widespread use of flow cytometry for disease diagnosis and early detection, adoption in stem cell research is propelling the growth of the Flow cytometry Market.
• An increase in government funding for clinical studies related to in vitro molecular diagnostics is expected to drive the market, as it plays an important role in the development of new products. Increased investment in well-known biotech and biopharma firms has resulted in significant Flow Cytometry market growth.
• Most end-users, such as clinical laboratories, large research facilities, and pharmaceutical companies, require a large number of flow cytometry instruments in order to conduct multiple research studies at the same time. As a result, the capital costs associated with the acquisition and maintenance of these devices soar. Due to limited budgets, such instruments are difficult to obtain for academic and research laboratories.

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates and Analyses the Data collected by means of Primary Exploratory Research backed by the robust Secondary Desk research.

According to our analysis, the global flow cytometry market is expected to expand at a rapid pace in the coming years, owing to technological advancements and widespread adoption in a variety of research and diagnostic applications. Moreover, the application of flow cytometry technology in novel research applications such as cytogenomics, proteomics, and marine cell biology would contribute to the industry's expansion. Furthermore, rising disease incidence rates, such as cancer and HIV, are expected to drive the adoption of flow cytometry technology across diagnostic applications.